Targovax receives Fast Track designation for ONCOS-102 in melanoma

Corporate Breaking News

Home : Targovax receives Fast Track designation for ONCOS-102 in melanoma

Jun 22 2021	Targovax receives Fast Track designation for ONCOS-102 in melanoma
OSLO, Norway, June 22, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast Track designation in...


Source:https://www.prnewswire.com:443/news-releases/targovax-receives-fast-track-designation-for-oncos-102-in-melanoma-301316948.html

Related News
» Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira® » Thermo Fisher Scientific lance le test TaqPath COVID-19 2.0 de nouvelle génération marqué CE-IVD